[go: up one dir, main page]

ATE92316T1 - Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien. - Google Patents

Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.

Info

Publication number
ATE92316T1
ATE92316T1 AT89830544T AT89830544T ATE92316T1 AT E92316 T1 ATE92316 T1 AT E92316T1 AT 89830544 T AT89830544 T AT 89830544T AT 89830544 T AT89830544 T AT 89830544T AT E92316 T1 ATE92316 T1 AT E92316T1
Authority
AT
Austria
Prior art keywords
medication
manufacture
therapeutic treatment
peripheral neuropathies
carnitine derivatives
Prior art date
Application number
AT89830544T
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE92316T1 publication Critical patent/ATE92316T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT89830544T 1988-12-27 1989-12-13 Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien. ATE92316T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8848717A IT1224842B (it) 1988-12-27 1988-12-27 Uso di derivati della l-carnitina nel trattamento terapeutico delle alterazioni degenerative del sistema nervoso
EP89830544A EP0376899B1 (de) 1988-12-27 1989-12-13 Verwendung von L-Carnitinderivaten zur Herstellung eines Arzneimittels zur therapeutischen Behandlung von peripheren Neuropathien

Publications (1)

Publication Number Publication Date
ATE92316T1 true ATE92316T1 (de) 1993-08-15

Family

ID=11268228

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89830544T ATE92316T1 (de) 1988-12-27 1989-12-13 Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.

Country Status (9)

Country Link
US (1) US5043355A (de)
EP (1) EP0376899B1 (de)
JP (1) JP2828293B2 (de)
AT (1) ATE92316T1 (de)
DE (1) DE68908145T2 (de)
ES (1) ES2058596T3 (de)
HK (1) HK1005849A1 (de)
IT (1) IT1224842B (de)
ZA (1) ZA899802B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245699B (it) * 1991-05-29 1994-10-14 Sigma Tau Ind Farmaceuti Derivati della l-carnitina quali agenti terapeutici per il trattamento delle miopatie, della degenarazione neuronale e per inibire la proteolisi
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
IT1263004B (it) * 1992-10-08 1996-07-23 Sigma Tau Ind Farmaceuti Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
IT1277898B1 (it) * 1995-08-03 1997-11-12 Mendes Srl Uso di amminoacidi basici, di acil derivati di amminoacidi basici e di loro sali farmaceuticamente accettabili per la profilassi di malattie
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
IT1276253B1 (it) 1995-12-15 1997-10-27 Sigma Tau Ind Farmaceuti Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
IT1283951B1 (it) * 1996-03-15 1998-05-07 Mendes Srl Uso della acetil l-carnitina o dei suoi sali farmacologicamente accettabili per il trattamento terapeutico o la profilassi di
IT1291113B1 (it) * 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US6090848A (en) * 1997-12-01 2000-07-18 Sigma-Tau Healthscience S.P.A. Compositions and methods for increasing the concentration and/or motility of spermatozoa in humans
US5863940A (en) 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
PT951909E (pt) 1998-03-19 2004-04-30 Sigma Tau Ind Farmaceuti Composicao combinada que contem uma l-carnitina ou uma alcanoil-l-carnitina um glicosaminoglicano e/ou um seu constituinte
US8173618B2 (en) * 2003-07-25 2012-05-08 University Of Massachusetts Formulations for reducing neuronal degeneration
ITRM20040327A1 (it) * 2004-07-01 2004-10-01 Sigma Tau Ind Farmaceuti Uso della acetil l-carnitina per la preparazione di un medicamento per il trattamento del dolore neuropatico in pazienti diabetici.
WO2007043339A1 (en) * 2005-09-30 2007-04-19 Showa Denko K.K. Carnitine derivative, salt thereof, external skin preparation and cosmetic material
JP5047507B2 (ja) * 2005-09-30 2012-10-10 昭和電工株式会社 カルニチン誘導体及びその塩、皮膚外用剤ならびに化粧料
US8597640B2 (en) * 2007-10-31 2013-12-03 University Of Massachusetts Lowell Over-the-counter vitamin/nutriceutical formulation that provides neuroprotection and maintains or improves cognitive performance in alzheimer's disease and normal aging
US20200129464A1 (en) * 2018-10-29 2020-04-30 Lonza Inc. Method and Composition for Increasing the Bioavailability of Carnitine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903579A1 (de) * 1978-02-03 1979-08-09 Sigma Tau Ind Farmaceuti Verwendung von acetylcarnitin und anderen acylderivaten des carnitins zur behandlung der hyperlipoproteinaemie und hyperlimpidaemie sowie arzneimittel
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
IT1116037B (it) * 1979-04-23 1986-02-10 Sigma Tau Ind Farmaceuti Esteri e ammidi di acil carnitine loro procedimenti di preparazione e loro uso terapeutico
IT1150396B (it) * 1982-12-09 1986-12-10 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico di miopa tie e distrofie muscolari
IT1181682B (it) * 1985-06-11 1987-09-30 Sigma Tau Ind Farmaceuti Impiego di alcanoil l-carnitine per il trattamento terapeutico del parkinsonismo idiopatico o indotto
IT1208753B (it) * 1986-07-02 1989-07-10 Sigma Tau Ind Farmaceuti L-amminoacil derivati della l-carnitina, procedimento per la loro preparazione e composizioni farmaceutiche ad attivita' epatoprotettrice che li contengono
IT1196564B (it) * 1986-08-04 1988-11-16 Sigma Tau Ind Farmaceuti Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche

Also Published As

Publication number Publication date
DE68908145D1 (de) 1993-09-09
JPH02207020A (ja) 1990-08-16
IT8848717A0 (it) 1988-12-27
ZA899802B (en) 1990-11-28
EP0376899A3 (de) 1991-09-18
JP2828293B2 (ja) 1998-11-25
ES2058596T3 (es) 1994-11-01
DE68908145T2 (de) 1993-11-25
EP0376899B1 (de) 1993-08-04
HK1005849A1 (en) 1999-01-29
US5043355A (en) 1991-08-27
EP0376899A2 (de) 1990-07-04
IT1224842B (it) 1990-10-24

Similar Documents

Publication Publication Date Title
ATE92316T1 (de) Verwendung von l-carnitinderivaten zur herstellung eines arzneimittels zur therapeutischen behandlung von peripheren neuropathien.
ATE83659T1 (de) Verwendung von indolon-derivaten zur herstellung von arzneimitteln zur behandlung des parkinsonismus.
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
ATE121744T1 (de) Neue triazolopyrimidin- und pyrazolopyrimidinderivate zur behandlung von kachexie.
HK1011967A1 (en) Amide derivatives having anti-hyper cholesteremic activity their preparation and their therapeutic uses
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ATE205712T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der angiogenese und angiogene krankheiten
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
DE58906387D1 (de) Verwendung von Benzimidazolen zur Herstellung eines Arzneimittels mit antiischämischen Wirkungen am Herzen und dessen Kombinationen mit Beta-Blockern oder Bradycardica.
DE59206403D1 (de) Verwendung von Xanthinderivaten zur Herstellung eines Arzneimittels zur Behandlung von sekundären Nervenzellschäden und Funktionsstörungen nach Schädel-Hirn-Traumen
ATE135573T1 (de) Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten
DE69222570D1 (de) Phosphonsäurederivate, Verfahren zur Herstellung und ihre Verwendung
DE69419954D1 (de) Arzneimittel zur Behandlung von Hauterkrankungen
ES8604960A1 (es) Procedimiento para preparar derivados de 1,6-naftiridina
DE69906728D1 (de) Verwendung von 4-piperidinmethanolderivaten zur behandlung von neuralentwicklungsstörungen
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
IE800900L (en) Pyrrolidinyl-benzoic acid derivatives.
ATE81466T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur prophylaxe und zur behandlung von herzinsuffizienz.
ATE265212T1 (de) Verwendung von 4-acylaminopyridin derivaten zur herstellung eines medikaments für die behandlung von zerebrovaskulären erkrankungen
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
ATE106727T1 (de) Verwendung eines benzo(b>thiophen-2- carboximidamid-derivates gegen herzinsuffizienz.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time